You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
Free

 

Online download statistics by month:

Online download statistics by month: December 2020 to April 2024

AbstractFullPdf
Dec 202092021
Jan 20215408
Feb 20214807
Mar 20213903
Apr 202180011
May 20212002
Jun 2021203
Jul 2021109
Aug 2021206
Sep 2021006
Oct 202136017
Nov 202160017
Dec 20215706
Jan 20226207
Feb 20228506
Mar 20227803
Apr 2022128010
May 202282016
Jun 2022122016
Jul 2022115024
Aug 202212409
Sep 2022109012
Oct 202274010
Nov 202211609
Dec 2022130012
Jan 2023115012
Feb 202311607
Mar 2023128018
Apr 2023115014
May 202311907
Jun 20238203
Jul 2023112017
Aug 20239007
Sep 20238807
Oct 202312304
Nov 202373013
Dec 20237806
Jan 20245202
Feb 20244706
Mar 202470026
Apr 20244008
Total31640407